Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
About MARA Rating: We provide an independent Market‑Access Risk Assessment (A++ → C) built on a transparent, 10‑domain HTA framework. Use the score to benchmark an asset’s access prospects against
MARA Rating Insight: Why Resource Use & Cost Implications Decide Coverage Since 2020, one pattern has been clear in our database: Assets averaging 2.8 in Resource Use & Cost progressed through HTA
MARA Rating’s Care Pathway Integration score (A++–C) predicts HTA endorsement and payer adoption by measuring clinical guideline alignment, workflow efficiency, administration ease, and implementation feasibility. Too often, M&A teams under-weight
MARA Rating’s Patient Population score (A++–C) predicts HTA approval & reimbursement success. Learn how robust subgroup analysis and real-world evidence drive payer confidence. Too often, M&A teams under-weight market-access risk—patient
MARA Rating in the Workflow: How Market Access & BD Teams Use It to Make Better Asset Calls (MARA Rating stands for Market Access Risk Assessment Rating.) Most valuations overweight
Independent MARA® Ratings quantify HTA reimbursement risk for pharma assets. 5-year 97% precision across 10 domains. Request your report today. MARA Rating Insight Since 2020, assets averaging a 2.9 Comparator Selection score sailed
Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety
Every payer’s checklist is different. This week: Health-Related Quality of Life—how patient experience shapes coverage. MARA Rating Insight: Since 2020, drugs averaging a 2.8 HRQoL score secured reimbursement far more often than those
An overview of how different payers prioritize safety and tolerability profiles when assessing new therapies. MARA Rating Insight Since 2020, assets averaging a 3.3 Safety score cleared HTA hurdles more often than those
A concise overview of the essential Health Technology Assessment domains every drug developer must address. Use this checklist to design and execute development programs that directly address payer needs across